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BACKGROUND: Readmissions after radical cystectomy are common, burdensome, and poorly understood. For these reasons,
the authors conducted a population-based study that focused on the causes of and time to readmission after radical cystectomy.
METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, at total of 1782 patients who underwent radical cystec-
tomy from 2003 through 2009 were identified. A piecewise exponential model was used to examine reasons for readmission as well
as patient and clinical factors associated with the timing of readmission. RESULTS: One in 4 patients (25.5%) were readmitted within
30 days of discharge after radical cystectomy. Compared with patients without readmission, those readmitted were similar with
regard to age, sex, and race. Readmitted patients had more complications (33.8% vs 13.9%; P<.001) and were more likely to have
been discharged to skilled nursing facilities from their index admission (P< .001). The average time to readmission and subsequent
length of stay were 11.5 days and 6.7 days, respectively. The majority of readmissions (67.4%) occurred within 2 weeks of discharge,
66.8% had emergency department charges, and 25.9% involved intensive care unit use. Although the spectrum of reasons for read-
mission varied over the 4 weeks after discharge, the most common included infection (51.4%), failure to thrive (36.3%), and urinary
(33.2%) and gastrointestinal (23.1%) etiologies; 95.8% of patients had 1 of these diagnosis groups present at the time of readmission.
CONCLUSIONS: Readmissions after radical cystectomy are common and time-dependent. Interventions to prevent and reduce the
readmission burden after cystectomy likely need to focus on the first 2 weeks after discharge, take into consideration the spectrum
of reasons for readmission, and target high-risk individuals. Cancer 2014;120:1409–16. VC 2014 American Cancer Society.
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INTRODUCTION
Hospital readmissions are increasingly scrutinized as drivers of health care spending.1,2 They comprise nearly one-half of
all hospitalizations and many are believed to be preventable.3-5 In fact, preventable readmissions are responsible for an esti-
mated $25 billion in unnecessary health care costs,6 not to mention a significant burden on patients and caregivers. As
efforts to reduce unnecessary spending mount, policies such as the Patient Protection and Affordable Care Act (ACA)
have redoubled efforts to improve the readmission landscape. After ACA implementation, the Centers for Medicare and
Medicaid Services (CMS) will now penalize hospitals with higher-than-expected 30-day readmission rates.7 This policy
has encouraged health care organizations to more actively evaluate and implement solutions to minimize hospital
readmissions.
Cystectomy, a complicated surgical procedure entailing bladder removal and urinary tract reconstruction, is associ-
ated with one of the highest readmission rates of any surgery at approximately 25%.8-10 Unfortunately, rates have
remained stable over the past decade and current research offers limited insight into how best to reduce this burden.10
One way to inform solutions might be to study in more detail when and why readmissions occur. However, clinical data
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are often constrained by small sample sizes and most
claims-based research examines readmissions at blunt cut-
off values (eg, 30 days) when in reality patients are at risk
of readmission each day after discharge and for a variety of
reasons. A better understanding of readmissions after cys-
tectomy may help to direct the type and intensity of post-
discharge care to reduce their burden.
For these reasons, we conducted a population-based
study that focused on the time to and causes of readmis-
sion after radical cystectomy. We examined how patient
and clinical factors, including complications, were related
to the timing of readmissions and provide previously
unexplored details regarding resource use during readmis-
sion. Overall, this study sought to inform tailored inter-
ventions to prevent unnecessary readmissions and reduce
the intensity of readmission for those in need of hospital
care after cystectomy.
MATERIALS AND METHODS
Study Population
We used Surveillance, Epidemiology, and End Results-
Medicare data to identify patients undergoing cystectomy
(International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] codes 57.7, 57.71,
57.79, and 68.8) to treat bladder cancer between 2003
and 2009.11 We followed beneficiaries’ hospital-based
medical care over time using the Medicare Provider Anal-
ysis and Review (MedPAR) files. We included patients
between the ages of 66 and 99 years who were continu-
ously enrolled in both Medicare Parts A and B during the
period 12 months before and 6 months after their cystec-
tomy date and whose only malignancy was bladder cancer.
Patients in the Medicare Advantage program (n5 324)
were excluded to ensure all health care was ascertained, as
were those who died within 6 months of diagnosis. To
examine whether significant selection bias existed in our
final cohort, we compared age, race, sex, and pathologic
stage of disease among those with and without Medicare
Advantage coverage. We found no differences in age, race,
or sex across the groups; however, unknown pathologic
disease stage was more common among patients included
in the current study (data not shown). Applying these
criteria resulted in a study population of 1782 patients.
Postoperative Complications
We posited that a significant predictor of readmission was
whether a postoperative complication occurred during the
index hospitalization for radical cystectomy.8,12,13 For
this reason, we measured specific postoperative complica-
tions based on prior work using ICD-9-CM codes14 for
the following: acute renal failure and cardiac, gastrointes-
tinal, genitourinary, neurological, wound, and miscellane-
ous technical complications, as well as postoperative
hemorrhage, infection, pulmonary failure, and sepsis.
Postoperative complications were then classified into
medical, surgical, major, and any categories for our analy-
ses based on previously published work.14 Major compli-
cations included pulmonary, cardiac, acute renal failure,
venous thromboembolism, gastrointestinal, sepsis, wound,
iatrogenic injury, and hemorrhage.
Outcomes
The primary outcomes for this study were 30-day read-
missions and time to readmission, defined as the number
of days between discharge from a patient’s index cystec-
tomy hospitalization and subsequent readmission. We
defined readmission as rehospitalization to any acute care
hospital within 30 days of the index discharge date. Thus,
we did not consider postdischarge admission to skilled
nursing facilities (SNFs) or other similar destinations as a
readmission. However, any subsequent hospital admis-
sion among these patients was classified as a readmission.
We used a combination of discharge destination codes
and the MedPAR SNF indicator to guide our classifica-
tion algorithm. In general, discharge destination codes of
03, 04, 05, 61, 62, 63, 65, and 70 corresponded to subse-
quent SNF admissions. We used time to readmission in
days to classify readmissions into 4 groups based on
week(s) after discharge (weeks 1-4). This framework pro-
vided us with information regarding how the characteris-
tics of the readmission changed over time, including
readmitting diagnoses as well as patient and clinical fac-
tors associated with each readmission.
As a secondary outcome, 2 investigators (T.A.S. and
B.L.J.) classified readmission diagnoses from ICD-9-CM
codes in the MedPAR claims into 13 categories based on
clinical relevance to the postcystectomy population and
opportunity for targeted intervention: infection, meta-
bolic/endocrine, failure to thrive, urinary, hematologic,
cardiac, pulmonary, gastrointestinal, neurologic/psycho-
logic/musculoskeletal/ophthalmologic/otorhinolaryngo-
logic, vascular, wound/hematoma, female genitourinary/
gynecologic, and other (available on request). In particu-
lar, we conducted a sensitivity analysis to identify ICD-9-
CM codes that were present at the time of readmission
but were not present during the index cystectomy admis-
sion to optimize our detection of new diagnoses related to
the readmission. Because neoadjuvant chemotherapy
could also impact perioperative outcomes, we used ICD-
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9-CM codes in the outpatient files to identify 2 neoad-
juvant chemotherapy claims within 6 months of surgery.
Statistical Analysis
We used chi-square and Student t tests to identify rela-
tionships between 30-day readmission and patient and
index hospitalization characteristics including age (66-69
years, 70-74 years, 75-80 years, and> 80 years), sex, race
(white, African American, and other/unknown), socioeco-
nomic status (SES) (low, medium, and high), marital sta-
tus (yes/no), number of comorbidities (0, 1, and 2),
intensive care unit (ICU) use, end-stage renal disease/
hemodialysis, whether a computed tomography (CT)
scan was performed (yes/no), neoadjuvant chemotherapy
(yes/no), pathologic stage of disease, blood transfusion
(yes/no), length of stay (LOS), and discharge to a SNF
(yes/no). We determined each patient’s comorbidity bur-
den by evaluating diagnoses from their Medicare claims
for the 12 months preceding their surgery.15 We deter-
mined SES using each patient’s ZIP code according to the
approach of Diez-Roux et al.16
To assess significant predictors of readmission in
particular weeks after the index hospitalization, we used a
piecewise exponential model.17 We selected this approach
to account for discrete time data given the exact time of
readmission within an interval was known. We first classi-
fied the readmission history for each patient regardless of
readmission status into a set of discrete time units based
on the number of weeks from discharge (1 week-4 weeks
excluding days 29 and 30) to account for censoring. These
readmission indicators were treated as a distinct observa-
tion for each patient, with the time reset to 0 at the begin-
ning of the week. For example, patients who were not
readmitted were represented with 4 zeroes (0, 0, 0, and 0)
versus a patient readmitted in week 3 represented by 2
zeroes and 1 (0, 0, and 1). For each observation, if no
readmission occurred in the week, a time variable was
assigned to a full 7 days. If a readmission occurred, the
time variable was coded as the number of days from the
start of the week until the readmission. In cases of multi-
ple readmissions, the initial readmission was used.
After pooling all observations, we conducted a back-
ward model building procedure to determine which fac-
tors had significant effects on readmission, and examine
whether each factor’s effect differed depending on the
week of readmission by including the interaction terms
between readmission predictors and weeks. For example,
we examined whether the effects of a SNF varied over
time (SNF [yes/no]3 readmission week [1-4]). Factors in
our starting model included any complication present
during the index admission (yes/no), new diagnoses pres-
ent at the time of readmission (13 groups), age, sex, mari-
tal status, race, ICU and CT scan use, neoadjuvant
chemotherapy, pathologic disease stage, blood transfu-
sions, SNF, comorbidity, LOS, and SES. ICU use, CT
scan use, blood transfusions, and LOS all refer to the
index admission.
All analyses were performed using SAS statistical
software (version 9.3; SAS Institute Inc, Cary, NC) and
all testing was 2-sided. The probability of a type I error
was set at 0.05. The University of Michigan Institutional
Review Board approved the study protocol.
RESULTS
During the study period, 1 in 4 patients (25.5%) under-
going cystectomy were readmitted within 30 days of dis-
charge (Table 1). We found that characteristics such as age,
sex, race, SES, comorbidity, neoadjuvant chemotherapy,
pathologic stage, ICU use, end-stage renal disease/
TABLE 1. Patient and Clinical Characteristics
According to 30-Day Readmission Status
Characteristic
Readmission
Pa
No
n51327
Yes
n5455
Age, % .44
66-69 y 18.1 15.0
70-74 y 26.8 27.0
75-80 y 33.1 35.8
>80 y 22.0 22.2
Sex (male), % 73.8 76.5 .25
Married, % 69.9 69.3 .79
Race, % .93
White 90.9 91.3
African American 3.8 3.9
Other/unknown 5.3 4.8
SES, % .15
Low 32.3 28.2
Medium 34.0 33.6
High 33.7 38.2
Comorbidity, % .13
0 51.9 47.4
1 28.0 28.4
2 20.1 24.2
Pathologic stage, % .37
T1 25.2 29.5
T2-T4 63.0 62.1
Unknown 11.8 8.4
Discharge to SNF, % 7.8 22.6 <.001
Intensive care, % 65.8 68.8 .24
CT scan, % 19.8 24.4 .04
Blood transfusion, % 5.1 6.2 .37
Length of stay, d 11.1 11.5 .29
Neoadjuvant chemotherapy, % 7.9 6.5 .34
CT indicates computed tomography; SES, socioeconomic status; SNF,
skilled nursing facility.
a Chi-square test and Student t test for length of stay.
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hemodialysis, blood transfusions, and LOS for the index
hospitalization were not associated with 30-day readmis-
sion (all P> .10). However, readmitted patients were more
likely to have been discharged to SNFs compared with
patients who were not readmitted (22.6% vs 7.8%;
P< .001) and more likely to have had a CT scan during
their index admission (24.4% vs 19.8%; P5 .04). The
rates of any complication during the index hospitalization
exceeded 50% as shown in Table 2.14 The 5 most common
postoperative complications were genitourinary (21.8%),
gastrointestinal (17.9%), acute renal failure (16.1%), infec-
tion (12.3%), and sepsis (12.3%). Moreover, the majority
of complications we examined were more likely to be pres-
ent among readmitted patients. For example, compared
with those who were not readmitted, readmitted patients
demonstrated a nearly 2-fold increase in medical complica-
tions after surgery (17.6% vs 34.9%; P< .01) and a nearly
3-fold increase in wound complications (23.3% vs 59.6%;
P< .01).
With respect to readmissions, we found that the ma-
jority (67.4%) occurred within 2 weeks of discharge,
66.8% of readmissions had emergency department
charges, and 25.9% of readmissions involved ICU use
(Table 3). The average LOS for readmission after cystec-
tomy in the current study was 1 week and the median
time to readmission was 10 days. As a sensitivity analysis,
we classified LOS into quartiles (25% percentile indicates
an LOS of< 8 days; 25%-75% percentile indicates a LOS
of 8-11 days; and> 75% percentile indicates a LOS
of> 11 days) and examined readmission across the cate-
gories. There were no differences noted among the groups
with respect to readmission (P5 .18). We also examined
readmissions among optimal patients (ie, those without
any complications and LOS within 1 day of the median
[n5 274; 15.4%]). We found these patients were signifi-
cantly less likely to be readmitted to the hospital com-
pared with other patients (12.0% vs 28.0%; P< .001).
TABLE 2. Complications During Initial Hospitalization for Cystectomy and Subsequent Readmission
Complication Type
Complication Present During Index Hospitalization
Total No. of Patients
With Complication (%)No. (% Readmitted) Yes (% Readmitted)
Any complication 13.9 33.8 1042 (58.5)
Any medical complication 17.6 34.9 820 (46.0)
Any surgical complication 22.7 32.5 517 (29.0)
Any major complicationa 17.3 36.0 786 (44.1)
Genitourinary 24.9 27.8 389 (21.8)
Gastrointestinal 24.6 29.9 318 (17.9)
Acute renal failure 23.1 38.5 286 (16.1)
Sepsis 23.2 42.0 219 (12.3)
Infection 22.9 44.3 219 (12.3)
Bleeding 25.8 21.7 120 (6.7)
Wound 23.3 59.6 109 (6.1)
aMajor complications included pulmonary, cardiac, acute renal failure, venous thromboembolism, gastrointestinal, sepsis, wound, iatrogenic injury, and hemor-
rhage.14 In accordance with Surveillance, Epidemiology, and End Results (SEER)-Medicare rules, the following complications involving <5% of total patients
were suppressed: pulmonary (4.3%), other (3.2%), cardiac (2.7%), and neurologic (1.3%). The sepsis and infection categories were not mutually exclusive; the
total percentage of patients with such complications combined was 20.4%.
TABLE 3. Readmission Characteristics After Radi-
cal Cystectomy
Readmission Characteristics %
Emergency room charge 66.8
Intensive care 25.9
CT scan 53.4
Discharge to SNF (after readmission) 21.8
Mean initial length of stay (median), d 11.5 (9)
Mean readmission length of stay (median), d 6.7 (5)
Mean time to readmission (median), d 11.5 (10)
Readmitted in wk 1 40.4
Readmitted in wk 2 27.0
Readmitted in wk 3 16.0
Readmitted in wk 4 13.9
New diagnoses at time of readmission
(ie, reasons for readmission)
Infection 51.4
Failure to thrive 36.3
Urinary 33.2
Gastrointestinal 23.1
Hematologic 16.9
Metabolic 16.5
Wound related/hematoma 13.9
NPMO 13.9
Vascular 11.7
Cardiac 10.8
Pulmonary 9.2
Abbreviations: CT, computed tomography; NPMO, neurologic, psychologic,
musculoskeletal, ophthalmologic, and/or otorhinolaryngologic; SNF, skilled
nursing facility.
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As illustrated in Figure 1, the reason for readmission
(ie, diagnosis category) depended on the time from dis-
charge. For example, infectious diagnoses were ultimately
most prevalent by 30 days. However, gastrointestinal and
failure to thrive diagnoses appeared as common in the first
5 days after discharge. The 4 most common new diagno-
ses at the time of readmission involved infection, failure to
thrive, and urinary and gastrointestinal etiologies. More-
over, we found that 95.8% of all 30-day readmissions had
diagnoses belonging to at least 1 of those 4 categories
(85.9% of patients had 1 of these groups as a new diag-
nosis at the time of readmission).
Based on our multivariable survival analysis, factors
found to be significant for 30-day readmission include
new diagnoses related to failure to thrive; urinary, gastro-
intestinal, NPMO, vascular, and wound diagnoses; index
admission ICU care; and the presence of any complication
during the index admission (Table 4). We also found that
infectious, metabolic, and pulmonary diagnoses and SES
were time-dependent factors based on their interaction
terms. In particular, patients with new infectious diagno-
ses at the time of readmission were less likely to be read-
mitted in week 1 than in week 4, indicating that
infections were not statistically significant contributors to
readmission during the first week, relatively speaking
(adjusted hazard ratio [aHR], 0.28; 95% confidence inter-
val [95% CI], 0.15-0.51). Pulmonary diagnoses were
mostly associated with readmission in the first week after
discharge (aHR, 4.00; 95% CI, 1.28-12.52) when com-
pared with week 4, whereas metabolic diagnoses were less
common among patients readmitted in the first week
(aHR, 0.42; 95% CI, 0.20-0.90). Finally, compared with
high SES patients, patients with low SES were less likely
to be readmitted within the first 3 weeks after discharge
(Table 4).
DISCUSSION
This population-based study found that 1 in 4 patients
undergoing cystectomy was readmitted to the hospital
within 30 days regardless of their age, race, sex, and baseline
comorbidity. Our analyses revealed that approximately
two-thirds of the 30-day readmissions occurred within the
first 2 weeks after hospital discharge. Not surprisingly,
complications during the index admission were much
more common among readmitted patients and associated
with a 2-fold increase in the adjusted likelihood of readmis-
sion. As demonstrated in the current study, it was not
uncommon for patients to incur emergency room charges,
ICU use, and cross-sectional imaging during their readmis-
sion, which might last a week or more. The current study
findings and time-dependent analyses highlight that reduc-
ing the burden of readmissions among patients who under-
went cystectomy, caregivers, and health care systems is a
complex target. Successful interventions to prevent and
reduce the intensity of readmission after cystectomy will
likely need to focus on the first 2 weeks after discharge, take
into consideration the spectrum of diagnoses identified in
the current study, and be tailored to high-risk individuals.
The current study provides an in-depth examination
of 2 key elements contributing to readmission after
Figure 1. Trends in readmission diagnoses after radical cystectomy for bladder cancer are shown. The highlighted area represents
the 2-week period during which 67.4% of readmissions occurred. The most common readmission diagnoses involved infection
(51%), failure to thrive (36%), and urinary (33%) and gastrointestinal (23%) etiologies, with 96% of readmitted patients having 1
of these diagnosis groups. The diagnostic spectrum varied during the 4 weeks after discharge as shown. GI indicates gastrointes-
tinal; Neur, neurologic; MSK, musculoskeletal, Oto, otorhinolaryngologic; Opth, ophthalmologic; Psy, psychologic.
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surgery for bladder cancer: postoperative complications
and common reasons for readmission (ie, infection, fail-
ure to thrive, and urinary and gastrointestinal etiologies).
The former is consistent with research using both clinical
and administrative data to examine the morbidity of cys-
tectomy.8,18-22 For example, our complication rate of
58% falls well within the ranges cited in the literature
(38%-64%).18,23,24
With respect to the reasons for readmission, our
population-based findings expand on those reported by
clinical series with respect to the possible causes and tim-
ing of readmission in at least 2 ways. First, one descriptive
study of readmitted patients (n5 200) after radical cys-
tectomy found that common reasons for readmission
within 30 days included ileus (10.8%), nausea/vomiting
(7.0%), pyelonephritis (7.5%), urinary tract infection
(7.0%), failure to thrive (5.4%), and dehydration (6.5%),
findings that are consistent with the findings of the cur-
rent study.8 We expanded on these findings by providing
a more precise look at the reasons for and the discrete tim-
ing of readmission (ie, weekly) at a population level to
inform possible interventions. Second, by taking readmis-
sion timing into consideration, we were able to identify
when the majority of 30-day readmissions occur (ie,
within 2 weeks) to hone in on the most efficient way to
prevent and reduce the burden of readmission. This is
within the context of a multicenter, prospective cohort
study that found the odds of avoidable readmissions
decreased by 32% with each additional month after dis-
charge (odds ratio, 0.68; 95% CI, 0.58-0.81), suggesting
that earlier preventive efforts may be more productive.25
We also highlight the extreme resource use associated
with readmission after cystectomy (eg, ICU, emergency
department, and imaging) as a call to sharpen the focus on
not only reducing readmissions but also decreasing the in-
tensity of readmission for those in need of hospital care.
Reducing readmissions after bladder cancer surgery
will not only benefit patients and their caregivers but also
health care systems.2 In light of recent policy reforms,
health care organizations are actively seeking to reduce
excess readmissions to avoid payment reductions. By way
of a modification to the Social Security Act, Section 3025
of the ACA established the Hospital Readmissions Reduc-
tion Program.7 As part of this program, the CMS was
mandated to reduce payments to Medicare inpatient pro-
spective payment system hospitals with excess readmis-
sions effective October 2012. Although the current focus
is on excess readmissions compared with adjusted national
averages for medical conditions of acute myocardial in-
farction, pneumonia, and heart failure, the CMS is finaliz-
ing plans to include acute exacerbations of chronic
obstructive pulmonary disease as well as elective total hip
and knee arthroplasty for fiscal year 2015. Although pre-
venting readmissions after bladder cancer surgery may
play a small part in solving the entire readmission di-
lemma, effective solutions may be generalizable to other
surgical patients as the CMS program expands its clinical
scope to include more surgical care.
Payers and health care organizations are already
working to reduce readmissions through transitional care
programs, improved discharge planning, postdischarge
interventions, high-risk patient identification, and teleme-
dicine.2,26 Based on the findings of the current study,
patients at high risk of readmission after cystectomy
TABLE 4. Multivariable Analysis of Factors Associ-
ated With Readmission After Cystectomy
Factor (Referent) Comparator aHR (95% CI)
Readmission diagnoses
Infectiona -
Metabolica -
Pulmonary -
NPMO 1.41 (1.07-1.87)
Urinary 1.51 (1.21-1.88)
Failure to thrive 1.61 (1.29-2.01)
Vascular 1.67 (1.25-2.23)
Gastrointestinal 2.19 (1.73-2.77)
Wound 2.56 (1.92-3.42)
Index intensive care 1.23 (1.00-1.51)
Any complication during
index hospitalization
1.92 (1.52-2.42)
SESa -
Readmission wka -
Infection diagnoses
by readmission wk
Wk 1 0.28 (0.15-0.51)
Wk 2 0.51 (0.27-0.97)
Wk 3 1.01 (0.49-2.06)
Wk 4 1.00
Metabolic diagnoses
by readmission wk
Wk 1 0.42 (0.20-0.90)
Wk 2 0.99 (0.48-2.07)
Wk 3 0.55 (0.22-1.35)
Wk 4 1.00
Pulmonary diagnoses
by readmission wk
Wk 1 4.00 (1.28-12.52)
Wk 2 2.00 (0.57-2.94)
Wk 3 1.30 (0.32-5.20)
Wk 4 1.00
Readmission wk by SES Wk 1a: Low 0.35 (0.17-0.73)
Wk 1a: Medium 1.02 (0.46-2.24)
Wk 1a: High 1.00
Week 2a: Low 0.30 (0.14-0.65)
Week 2a: Medium 0.93 (0.41-2.11)
Week 2a: High 1.00
Week 3a: Low 0.31 (0.13-0.73)
Week 3a: Medium 1.04 (0.43- 2.52)
Week 3a: High 1.00
95% CI, 95% confidence interval; aHR, adjusted hazard ratio; NPMO, neu-
rologic, psychologic, musculoskeletal, ophthalmologic, and/or otorhinolar-
yngologic; SES, socioeconomic status.
a Refer to interaction terms for significant effects. Main effects were as fol-
lows for readmission week: readmission week 1: aHR, 1.91 (95% CI, 1.52-
2.42); week 2: aHR, 4.55 (95% CI, 2.40-8.63); week 3: aHR, 2.84 (95% CI,
1.45-5.58); and week 4: referent.
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appear to be those with postoperative complications. In
addition to more sophisticated time-dependent and sys-
tems engineering approaches to predict individuals at
high readmission risk,27 focusing efforts on the cystec-
tomy population within the first 2 weeks after discharge
appears to be a good starting point. Other interventions,
such as physical rehabilitation before cystectomy (ie, pre-
habilitation), should be considered as possible compo-
nents of a multifaceted approach to reduce the burden of
readmission in this population.28 The evidence base and
best practices to reduce readmissions remain a work in
progress.
There are several potential limitations to the current
study. First, we used Medicare data and excluded patients
aged< 66 years to ensure adequate comorbidity profiling.
However, because the median age at bladder cancer diag-
nosis is 73 years and greater than one-half of the patients
in the current study were aged> 75 years, the current
study findings appear generalizable to the majority of
patients undergoing major surgery for bladder cancer.11
Second, there may be concerns with our classification of
postoperative complications based on administrative
claims. These should be allayed by the use of a well-vetted
methodology to detect postoperative complica-
tions14,29,30 and the finding that our complication rates
were consistent with those reported in smaller clinical se-
ries. Third, we did not examine any intervening telephone
or outpatient care that may have prevented readmission.
Although this warrants further study, we did find a variety
of factors associated with readmission that can potentially
help to direct follow-up care and lines of inquiry for tele-
medicine and outpatient interventions. Finally, we did
not characterize the type of urinary diversion performed
among this study population. However, the majority of
urinary diversions involve an ileal conduit with a bias to-
ward patients with bladder cancer.12 Furthermore, find-
ings from a benign and cancer-related cystectomy cohort
demonstrated no differences in readmission or 90-day
mortality according to diversion type.12
High readmission rates after radical cystectomy
continue to plague patients, caregivers, and health care
systems. The findings of the current study and time-
dependent analyses highlight that reducing the burden
of readmissions after bladder cancer surgery is a com-
plex target. We believe successful interventions to pre-
vent and reduce the intensity of readmission after
cystectomy likely need to focus on the first 2 weeks after
discharge, take into consideration the spectrum of diag-
noses in the current study, and be tailored to high-risk
individuals.
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